Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.430
+0.250 (7.86%)
At close: Jun 26, 2026, 4:00 PM EDT
3.420
-0.010 (-0.29%)
After-hours: Jun 26, 2026, 7:08 PM EDT
Prime Medicine Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Prime Medicine stock have an average target of 7.80, with a low estimate of 5.00 and a high estimate of 11. The average target predicts an increase of 127.41% from the current stock price of 3.43.
Analyst Consensus: Buy
* Price targets were last updated on May 12, 2026.
Analyst Ratings
The average analyst rating for Prime Medicine stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 8 | 8 | 8 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains n/a | Hold | Maintains | n/a | n/a | May 13, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $11 | Buy | Reiterates | $11 | +220.70% | May 12, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $5 | Buy | Reiterates | $5 | +45.77% | May 8, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $9 | Buy | Reiterates | $9 | +162.39% | May 8, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Buy Maintains $8 | Buy | Maintains | $8 | +133.24% | May 8, 2026 |
Financial Forecast
Revenue This Year
9.45M
from 4.63M
Increased by 104.04%
Revenue Next Year
19.77M
from 9.45M
Increased by 109.15%
EPS This Year
-0.98
from -1.35
EPS Next Year
-0.87
from -0.98
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 53.2M | 139.0M | |
| Avg | 9.5M | 19.8M | |
| Low | 856,000 | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1,047.6% | 1,370.7% | |
| Avg | 104.0% | 109.2% | |
| Low | -81.5% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.77 | -0.41 | |
| Avg | -0.98 | -0.87 | |
| Low | -1.18 | -1.40 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.